MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipeline

Sun Pharma’s June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly. Strategic initiatives like semaglutide launches and the Organon acquisition are key drivers. Despite US generics pressure, domestic business and specialty products show strong momentum. Analysts maintain a positive outlook, anticipating substantial growth from […]